--- title: "ORBUSNEICH's final dividend is expected to increase by 20% to 12 cents, planning to declare a regular interim dividend" type: "News" locale: "en" url: "https://longbridge.com/en/news/278998810.md" description: "ORBUSNEICH (6929) announced its results, declaring a final dividend of HKD 0.12 per share, a year-on-year increase of 20%. The company is considering the distribution of a regular interim dividend, but no specific ratio has been determined. The U.S. business is recovering rapidly and has entered the Middle Eastern market, with minimal impact from the U.S.-Iran war. The chairman stated that the company's advantage in the U.S. market lies in its global sales network. R&D expenses are expected to rise due to the initiation of clinical research in Japan. Revenue from the mainland has dropped by 13.9% due to the centralized procurement system, but the future impact is expected to be minor" datetime: "2026-03-13T07:18:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278998810.md) - [en](https://longbridge.com/en/news/278998810.md) - [zh-HK](https://longbridge.com/zh-HK/news/278998810.md) --- # ORBUSNEICH's final dividend is expected to increase by 20% to 12 cents, planning to declare a regular interim dividend ORBUSNEICH (6929) announced its results yesterday, declaring a final dividend of 12 cents per share, an increase of 20% year-on-year. Including the previously distributed special dividend of 15 cents for the company's 25th anniversary, the total dividend for last year was 27 cents. The company's Chief Operating Officer, Liu Guizhen, stated that the company is actively considering the distribution of a regular interim dividend to balance the company's situation and shareholder expectations, but there is currently no specific dividend ratio. ## Rapid Recovery of U.S. Business in the Second Half of Last Year The company has entered the Middle Eastern market, and she mentioned that the U.S.-Iran war has not had a significant impact on the company for the time being, as medical equipment is a necessity. Regarding the U.S. tariff war, the company's Chairman, Qian Yongxun, stated that one of the company's advantages is its balanced market distribution and its global sales network, with factories located in the Netherlands and Germany. Liu Guizhen added that the U.S. tariff war has allowed the company to have more layouts in drug registration locations and raw materials, and after the relaxation of U.S. tariff policies in the second half of last year, the company's business in the U.S. market has recovered quickly. In terms of acquisition and merger plans, Liu Guizhen pointed out that the company will explore related opportunities in areas such as sales networks, technology, and products, and does not rule out collaboration with partners, especially as the value of partners is highlighted in the context of geopolitical instability. She continued to say that the company already has a solid foundation in the Asia-Pacific region and expects to launch direct sales to hospitals in the Netherlands and Belgium within this year. ## Clinical Research in Japan to Start in July, R&D Spending Increases She mentioned that due to a clinical study in Japan starting in July, the company's R&D spending is expected to increase year-on-year this year, and as new products are gradually launched in Japan, revenue from Japan will regain growth momentum. The company's factory located in Hangzhou, China, is expected to start production next year, while the factory in Indonesia is in planning, with the intention to initially supply local market demand. ## Revenue from Mainland China Drops 13.9% Due to Product Inclusion in Centralized Procurement The company's revenue from mainland China dropped 13.9% year-on-year last year. The company's Chief Financial Officer, Chen Yongcheng, explained that this was due to products being included in China's centralized procurement system last year, but currently about 80% of the company's products have been included in the procurement system, and it is expected that the impact of this system on the company in the future will be minimal ### Related Stocks - [06929.HK](https://longbridge.com/en/quote/06929.HK.md) ## Related News & Research - [Exploring Three Undiscovered Gems in the Middle East Market](https://longbridge.com/en/news/286881831.md) - [CAN Community Health Launches Healx Solutions to Expand Access in Specialty Therapy Services](https://longbridge.com/en/news/287218904.md) - [EXCLUSIVE-FDA drug center head expected to leave after commissioner's exit, sources say](https://longbridge.com/en/news/286589761.md) - [00:45 ETAraceli Biosciences Launches Endeavor® Live Cell for Ultra-High-Throughput Kinetic Imaging in AI-Driven Drug Discovery](https://longbridge.com/en/news/287006505.md) - [Kivo Launches Headless GxPTM to Power Compliant Agentic AI in Drug Development](https://longbridge.com/en/news/287071239.md)